165 related articles for article (PubMed ID: 33037136)
1. Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A.
Thompson PA; Eam B; Young NP; Fish S; Chen J; Barrera M; Howard H; Sung E; Parra A; Staunton J; Chiang GG; Gerson-Gurwitz A; Wegerski CJ; Nevarez A; Clarine J; Sperry S; Xiang A; Nilewski C; Packard GK; Michels T; Tran C; Sprengeler PA; Ernst JT; Reich SH; Webster KR
Mol Cancer Ther; 2021 Jan; 20(1):26-36. PubMed ID: 33037136
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.
Steinhardt JJ; Peroutka RJ; Mazan-Mamczarz K; Chen Q; Houng S; Robles C; Barth RN; DuBose J; Bruns B; Tesoriero R; Stein D; Fang R; Hanna N; Pasley J; Rodriguez C; Kligman MD; Bradley M; Rabin J; Shackelford S; Dai B; Landon AL; Scalea T; Livak F; Gartenhaus RB
Blood; 2014 Dec; 124(25):3758-67. PubMed ID: 25320244
[TBL] [Abstract][Full Text] [Related]
3. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S
Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330
[TBL] [Abstract][Full Text] [Related]
4. Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors.
Gerson-Gurwitz A; Young NP; Goel VK; Eam B; Stumpf CR; Chen J; Fish S; Barrera M; Sung E; Staunton J; Chiang GG; Webster KR; Thompson PA
Front Oncol; 2021; 11():766298. PubMed ID: 34900714
[TBL] [Abstract][Full Text] [Related]
5. A novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1.
Tsai BP; Jimenez J; Lim S; Fitzgerald KD; Zhang M; Chuah CT; Axelrod H; Wilson L; Ong ST; Semler BL; Waterman ML
Open Biol; 2014 Nov; 4(11):140180. PubMed ID: 25392452
[TBL] [Abstract][Full Text] [Related]
6. eIF4B stimulates eIF4A ATPase and unwinding activities by direct interaction through its 7-repeats region.
Andreou AZ; Harms U; Klostermeier D
RNA Biol; 2017 Jan; 14(1):113-123. PubMed ID: 27858515
[TBL] [Abstract][Full Text] [Related]
7. Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax.
Herzog LO; Walters B; Buono R; Lee JS; Mallya S; Fung A; Chiu H; Nguyen N; Li B; Pinkerton AB; Jackson MR; Schneider RJ; Ronai ZA; Fruman DA
Br J Cancer; 2021 Mar; 124(6):1098-1109. PubMed ID: 33318657
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation.
Rubio CA; Weisburd B; Holderfield M; Arias C; Fang E; DeRisi JL; Fanidi A
Genome Biol; 2014; 15(10):476. PubMed ID: 25273840
[TBL] [Abstract][Full Text] [Related]
9. eIF4B stimulates translation of long mRNAs with structured 5' UTRs and low closed-loop potential but weak dependence on eIF4G.
Sen ND; Zhou F; Harris MS; Ingolia NT; Hinnebusch AG
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10464-72. PubMed ID: 27601676
[TBL] [Abstract][Full Text] [Related]
10. Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.
Ernst JT; Thompson PA; Nilewski C; Sprengeler PA; Sperry S; Packard G; Michels T; Xiang A; Tran C; Wegerski CJ; Eam B; Young NP; Fish S; Chen J; Howard H; Staunton J; Molter J; Clarine J; Nevarez A; Chiang GG; Appleman JR; Webster KR; Reich SH
J Med Chem; 2020 Jun; 63(11):5879-5955. PubMed ID: 32470302
[TBL] [Abstract][Full Text] [Related]
11. eIF4A1 Inhibitor Suppresses Hyperactive mTOR-Associated Tumors by Inducing Necroptosis and G2/M Arrest.
Han L; Wu Y; Liu F; Zhang H
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805935
[TBL] [Abstract][Full Text] [Related]
12. Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules.
Singh K; Lin J; Lecomte N; Mohan P; Gokce A; Sanghvi VR; Jiang M; Grbovic-Huezo O; Burčul A; Stark SG; Romesser PB; Chang Q; Melchor JP; Beyer RK; Duggan M; Fukase Y; Yang G; Ouerfelli O; Viale A; de Stanchina E; Stamford AW; Meinke PT; Rätsch G; Leach SD; Ouyang Z; Wendel HG
Cancer Res; 2021 Apr; 81(8):2002-2014. PubMed ID: 33632898
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model.
Bordeleau ME; Robert F; Gerard B; Lindqvist L; Chen SM; Wendel HG; Brem B; Greger H; Lowe SW; Porco JA; Pelletier J
J Clin Invest; 2008 Jul; 118(7):2651-60. PubMed ID: 18551192
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of small molecules targeting eIF4A.
Naineni SK; Itoua Maïga R; Cencic R; Putnam AA; Amador LA; Rodriguez AD; Jankowsky E; Pelletier J
RNA; 2020 May; 26(5):541-549. PubMed ID: 32014999
[TBL] [Abstract][Full Text] [Related]
15. The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape.
Modelska A; Turro E; Russell R; Beaton J; Sbarrato T; Spriggs K; Miller J; Gräf S; Provenzano E; Blows F; Pharoah P; Caldas C; Le Quesne J
Cell Death Dis; 2015 Jan; 6(1):e1603. PubMed ID: 25611378
[TBL] [Abstract][Full Text] [Related]
16. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
17. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein.
Jin C; Rajabi H; Rodrigo CM; Porco JA; Kufe D
Oncogene; 2013 Apr; 32(17):2179-88. PubMed ID: 22689062
[TBL] [Abstract][Full Text] [Related]
18. Programmed cell death 4 mechanism of action: The model to be updated?
Vikhreva PN; Kalinichenko SV; Korobko IV
Cell Cycle; 2017 Oct; 16(19):1761-1764. PubMed ID: 28853972
[TBL] [Abstract][Full Text] [Related]
19. Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
Oblinger JL; Burns SS; Akhmametyeva EM; Huang J; Pan L; Ren Y; Shen R; Miles-Markley B; Moberly AC; Kinghorn AD; Welling DB; Chang LS
Neuro Oncol; 2016 Sep; 18(9):1265-77. PubMed ID: 26951381
[TBL] [Abstract][Full Text] [Related]
20. A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A.
Yang HS; Cho MH; Zakowicz H; Hegamyer G; Sonenberg N; Colburn NH
Mol Cell Biol; 2004 May; 24(9):3894-906. PubMed ID: 15082783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]